Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
4.540
+0.340 (8.08%)
Nov 21, 2024, 11:29 AM EST - Market open

Telomir Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21
Net Income
-22.96-13.07-0.85-0.14
Other Amortization
5.081.61--
Other Operating Activities
7.477.49--
Change in Accounts Payable
0.130.110.390.02
Change in Other Net Operating Assets
-0.08-0--
Operating Cash Flow
-5.55-3.86-0.47-0.12
Short-Term Debt Issued
-3.170.460.12
Total Debt Issued
1.123.170.460.12
Short-Term Debt Repaid
--0.05--
Total Debt Repaid
-0.46-0.05--
Net Debt Issued (Repaid)
0.663.120.460.12
Issuance of Common Stock
5.9210.06-
Other Financing Activities
-0.2-0.26-0.05-
Financing Cash Flow
6.383.860.470.12
Net Cash Flow
0.83-00-
Free Cash Flow
-5.55-3.86-0.47-0.12
Free Cash Flow Per Share
-0.19-0.14-0.02-
Levered Free Cash Flow
0.21-1.96--
Unlevered Free Cash Flow
-1.68-2.55--
Change in Net Working Capital
-0.020.08--
Source: S&P Capital IQ. Standard template. Financial Sources.